Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
Share
Why It Matters
Novo Nordisk says its semaglutide drug protects hearts better than Eli Lilly's tirzepatide. This suggests semaglutide might be the stronger choice for patients worried about heart health.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.